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Abstract
Cellular reprogramming of somatic cells into induced pluripotent stem cells (iPSC) opens up new avenues for basic research
and regenerative medicine. However, the low efficiency of the procedure remains a major limitation. To identify iPSC, many
studies to date relied on the activation of pluripotency-associated transcription factors. Such strategies are either
retrospective or depend on genetically modified reporter cells. We aimed at identifying naturally occurring surface proteins
in a systematic approach, focusing on antibody-targeted markers to enable live-cell identification and selective isolation. We
tested 170 antibodies for differential expression between mouse embryonic fibroblasts (MEF) and mouse pluripotent stem
cells (PSC). Differentially expressed markers were evaluated for their ability to identify and isolate iPSC in reprogramming
cultures. Epithelial cell adhesion molecule (EPCAM) and stage-specific embryonic antigen 1 (SSEA1) were upregulated early
during reprogramming and enabled enrichment of OCT4 expressing cells by magnetic cell sorting. Downregulation of
somatic marker FAS was equally suitable to enrich OCT4 expressing cells, which has not been described so far. Furthermore,
FAS downregulation correlated with viral transgene silencing. Finally, using the marker SSEA-1 we exemplified that
magnetic separation enables the establishment of bona fide iPSC and propose strategies to enrich iPSC from a variety of
human source tissues.
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Introduction
Pluripotent stem cells have long been considered a potent source
for cell-based therapies. In 2006 Shinya Yamanaka’s ground-
breaking study paved the way to convert somatic cells into the so-
called induced pluripotent stem cells (iPSC) [1], opening up new
avenues for disease-specific drug modeling and patient-specific
therapies. Rapidly, iPSC technology was proven to be a versatile
tool for derivation of iPSC from healthy [2;3] and diseased [4;5]
individuals and a proof-of-principle study demonstrated successful
treatment of a genetic disorder via the iPSC interstage [6].
Reprogramming initiation was shown to be driven by a
mesenchymal-to-epithelial transition, followed by a maturation
phase before reaching a stably reprogrammed state [7–9]. An
elaborate study investigating changes in mRNA and miRNA
levels, histone modifications, and DNA methylation revealed that
respective changes preferentially occur in two distinct waves [10].
An associated proteome analysis likewise observed bi-phasic
expression changes and identified functional classes of proteins
being differentially expressed in distinct phases [10]. Downregu-
lation of fibroblast and mesenchymal markers was detected early
in reprogramming and upregulation of epithelial markers shortly
after [9;10]. Re-activation of several pluripotency-associated
transcription factors (e.g. OCT4, NANOG, SOX2) is typically
observed at intermediate or late stages of reprogramming
displaying some degree of variability in the predictability of single
markers for bona fide reprogrammed cells [10–14]. The first studies
succeeding in induction of mouse iPSC took advantage of
transgenic reporter systems linking reactivation of such pluripo-
tency-associated gene promoters to either drug selection [1;15–17]
or expression of fluorescent proteins [11;12] to identify the
reprogrammed cells. While iPSC generated from a Fbx15-based
reporter system failed to produce adult chimera, Oct4- and Nanog-
based systems allowed the successful generation of germline-
competent iPSC [1;15–17].
However, transgenic systems are labor-intense in their gener-
ation and cannot be employed when producing human iPSC for
clinical purposes, rendering naturally expressed surface proteins an
attractive alternative. Despite growing insight in gene expression
changes in general and proteome changes in particular, a limited
number of surface protein-based strategies have successfully been
implemented that allow the discrimination of cellular subsets in
reprogramming cultures. To date, no systematic investigation
aiming at the identification of antibodies with the ability to
discriminate reprogramming stages has been reported. MEFs
undergoing reprogramming were shown to phenotypically prog-
ress from a THY1
+ to a THY1
2/SSEA1
2 subpopulation,
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2/SSEA1
+ stage, ultimately achieving an
SSEA1
+/Oct4-GFP
+ phenotype [10;12]. Accordingly, SSEA1 was
successfully used to enrich for cells that had acquired pluripotency
[10–12], as were EPCAM, E-CADHERIN [18] and combinations
of PECAM1 with various other markers [19]. Likewise, a recent
publication demonstrated the suitability of PGP-1 (CD44) and
ICAM1 when combined with a Nanog-GFP-reporter [20]. SSEA1
and EPCAM were also successfully employed during directed
differentiation depriving iPS-derived neuronal cells of remaining
pluripotent cells of mouse and human origin, respectively [21;22].
In our study we sought to test a comprehensive library of 170
antibodies to identify surface proteins that are differentially
expressed between MEF and PSC. The differentially expressed
proteins should further be examined with regard to their dynamic
expression changes in the course of reprogramming and their
ability to enrich cells that are poised to become iPSC. Ultimately,
we aimed to bypass low reprogramming efficiencies thereby easing
the generation of iPSC lines.
Results
Twelve surface markers are differentially expressed
between PSC and MEF
An antibody screening experiment was performed to identify
surface markers that are expressed mutually exclusive on either
mouse PSC or MEFs, thereby potentially allowing the discrimi-
nation of PSC in the heterogeneous cell mixture of reprogram-
ming cultures. The screening was based on a library of 170
antibodies directed against mouse surface proteins (Table S1). The
library consisted of antibodies that had been generated in house
and commercially available antibodies, some of which were
selected due to their potentially differential expression previously
reported in the literature.
We compared expression by MEFs with the expression by
mouse ESC and iPSC lines. Surface proteins were considered as
potential reprogramming markers, if expression frequencies
reached more than 90% on positive cell types and below 30%
on the other cell types. Furthermore, markers were either
designated as ‘‘MEF associated’’ or ‘‘pluripotency associated’’
markers with respect to their expression characteristics in our
screening system. Beside the well described pluripotency associat-
ed marker SSEA1 and the MEF associated marker ITGAV
(Fig. 1A and S.K., unpublished data) 12 candidate markers were
identified. CEACAM1, ENG, C-KIT, DDR2, as well as the
previously described proteins E-CADHERIN and EPCAM were
identified as potential pluripotency associated markers. Six surface
proteins were categorized as potential MEF associated markers
(PGP-1, SELP, THY1.1, FAS, ALCAM and SCA-1) (Fig. 1B, C).
Of note, the THY1 genotype is strain-dependent in mice. While
CF1-MEFs expressed THY1.1, the Oct4-GFP (OG2)-MEFs
(C57Bl/6J x C3H/HeN background) expressed THY1.2 (Fig.
S1A). Though not meeting the aforementioned criteria, SELP was
included for further evaluation because of a high standard
deviation hampering interpretation. Interestingly, SELP was not
expressed on OG2-MEFs, while no unexpected expression of the
potential pluripotency associated markers was observed (Fig. S1A,
B). We point out that a lack of protein detection in the given screen
might also result from suboptimal antibody titers or specificity of
the employed antibody clones. Hence, it might still be possible to
detect some of the negatively tested proteins by different staining
protocols.
In conclusion, we identified 12 potential reprogramming
markers classifiable in MEF and pluripotency associated markers.
Definition of reprogramming stages by activation and
silencing of two combined reporter systems
A reliable system to identify reprogrammed cells was needed
before the expression characteristics of the candidate markers
could be investigated in the reprogramming process. Therefore, a
well-described Oct4-GFP pluripotency reporter mouse strain [23–
25] was employed, that had previously been shown to be activated
simultaneously or after silencing of lentiviral transgenes during
reprogramming [26]. We observed an Oct4-GFP signal in most
established iPSC that expressed OCT4 protein, but rarely in
absence of OCT4 protein. However, in both standard culture
(Fig. 2A) and differentiation-inducing conditions (Fig. 2B) many
cells were observed in which OCT4 protein was detectable despite
the absence of an Oct4-promoter dependent GFP signal. During
reprogramming progression Oct4-GFP expressing cells exclusively
arose as a subfraction of the OCT4 protein containing compart-
ment (Fig. 3A). Flow cytometric analysis of established iPSC lines
finally demonstrated co-expression of Oct4-GFP with OCT4
protein and SSEA1, respectively (Fig. 3C). Altogether, these
observations indicate that live cell detection of Oct4-GFP likely
underestimates the number of OCT4 expressing cells, most
pronounced during early reprogramming, thus representing a
very conservative marker of pluripotency induction in live cell
imaging approaches.
Reprogramming was achieved by lentiviral transduction of
hOct4,h Klf4,h Sox2 and hc-Myc (hOKSM), all co-expressed from a
single transgenic construct in which reprogramming factor
expression is linked by intergenic 2A peptides. In addition, a
terminally IRES-linked coding sequence of dimeric Tomato (Tom)
fluorescent protein enables tracking of reprogramming factor
expression [26]. At early time points (day 4 p.t.) most of the OCT4
protein expressing cells co-expressed the dTOMATO reporter,
while from day 9 p.t. the majority of OCT4-positive cells had
silenced transgenes as indicated by loss of dTOMATO expression
(Fig. 3D) suggesting reactivation of endogenous OCT4 synthesis.
Combining both reporter systems we found that dTOMATO
was strongly expressed in transduced cells. First Oct4-GFP positive
cells arose from this Tom
+ fraction at day 4 p.t. (Fig. 3D). The
mean fluorescence intensity pattern of dTOMATO altered over
time discriminating a Tom
high and a Tom
low subpopulation which
could clearly be distinguished from day 12 p.t. on. Importantly,
the Oct4-GFP
+ compartment was entirely Tom
low at that time
point and subsequently further downregulated dTOMATO,
indicating that this reporter combination represents a valuable
tool to follow temporal reprogramming progression. Thus, a
classification of the different reprogramming stages could be
implemented that features (1) a Tom
+ (single positive) early phase
of reprogramming (2) a Tom
+/GFP
+ double positive intermediate
phase and (3) an Oct4-GFP
+ single positive late reprogramming
stage. (4) Since from day 9 on far more cells expressed OCT4
protein as compared to Oct4-GFP or dTOMATO (Fig. 3A, B) an
alternative intermediate phase (Oct4-GFP
2/Tom
2 double nega-
tive) was concluded, reflecting that Oct4 promoter dependent GFP
detection succeeded transcriptional activation of endogenous
OCT4 expression. However, it is important to note that
reprogramming cultures also contained non-transduced cells.
Thus the Oct4-GFP
2/Tom
2 compartment consists of intermedi-
ate phase reprogrammed and untransduced cells. Due to a massive
reduction of autofluorescence in the reprogrammed cell fraction as
compared to the MEF population, the gating strategy for Oct4-
GFP and dTOMATO expressing cells was performed rather strict,
leaving out doubtful areas (total frequency of Oct4-GFP+ cells is
4.3% at day 15 p.t.).
FAS-Based Cell Depletion for Isolation of mIPS
PLOS ONE | www.plosone.org 2 July 2014 | Volume 9 | Issue 7 | e102171Figure 1. Identification of differentially expressed surface markers. A) A single flow cytometric analysis is shown to exemplify SSEA1 and
ITGAV expression properties (n.d. = not determined), both of which were previously shown to be differentially expressed between MEF and PSC. B)
Expression frequencies of antibody-targeted surface markers were tested by flow cytometry comparing MEFs (CF1), ESC line HM1 and iPSC line LV1-
7b (n=4 for MEFs: mean +/2 SD; n=2 for ESC/iPSC each). Given are the percentages of positive cells for identified candidate markers (6 potential
pluripotency associated markers on the left-hand side and 6 potential MEF associated markers on the right-hand side). Expression data of all
antibodies tested in the screen can be found in Table S1, additional expression characteristics on OG2-MEFs are shown in Figure S1. C) Representative
histograms are shown for selected markers.
doi:10.1371/journal.pone.0102171.g001
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reprogramming based on expression characteristics of reprogram-
ming factors and Oct4-GFP reporter signals.
EPCAM, SSEA1 and FAS expression changes reflect the
reprogramming stages
In order to investigate whether expression characteristics of the
12 candidate markers correlate with distinct stages of the
reprogramming process, the expression of all markers was
examined over time in the reprogramming stages defined above
(Fig. 3D). We found that the potential pluripotency associated
markers SSEA1 and EPCAM were gradually upregulated in the
course of reprogramming leading to partial expression in the
Tom
+/GFP
+ intermediate stage and high frequencies in the
Tom
2/GFP
+ late stage (Fig. 4A). While CEACAM1 was
upregulated only transiently, ENG failed to be upregulated at all
(Fig. S2). C-KIT and DDR2 were only expressed by a marginal
fraction of the Oct4-GFP
+ cells.
MEF associated markers FAS and THY1.2 were highly
expressed by untransduced OG2 cells, while striking downregu-
lation could be observed in reprogramming stages as early as day
4 p.t., ultimately resulting in expression frequencies below 14%
and 4% in the Tom
2/GFP
+ fraction, respectively (Fig. 4A and
Fig. S2). PGP-1 downregulation occurred rapidly and, notably, not
only in reprogramming but also untransduced cells lacking any
clear correlation with the reprogramming status (Fig. 4A). SCA-1
downregulation was incomplete as implicated by a dramatic drop
of the mean fluorescence intensity (not shown) while having little
effect on the population frequency. ALCAM was not downreg-
ulated in any fraction or at any point of time (data not shown).
ITGAV expression characteristics were difficult to interpret,
because of a low expression dynamic of ITGAV in day 12
reprogramming cultures. Furthermore, negative correlation of
ITGAV and OCT4 protein was incomplete (Fig. 4B). Conse-
quently, ITGAV was neglected for subsequent experiments.
FAS downregulation occurred in all Oct4-GFP and most OCT4
protein expressing cells 12 days p.t., demonstrating a negative
correlation between FAS and OCT4 protein (Fig. 4B, C). In
contrast, the EPCAM
+ subfraction predominantly correlated
positively with expression of OCT4 protein. Although the SSEA1
+
subfraction arose entirely from the cell population of OCT4
protein expressing cells, the majority of OCT4 protein expressing
cells did not yet express SSEA1. This might indicate that detection
of SSEA1 in our system lagged behind expression of OCT4
protein. Interestingly, the minority of Oct4-GFP expressing cells
co-expressed SSEA1 and vice versa. This might indicate that
SSEA1 and Oct4-GFP independently lag behind the expression of
OCT4 protein (as detailed above).
We concluded that expression characteristics of SSEA1,
EPCAM, FAS and THY1.2 are able to reflect reprogramming
progression with EPCAM upregulation and FAS downregulation
preceding the upregulation of SSEA1. We omitted ITGAV from
further analysis due to its insufficient dynamic range in expression
changes.
Establishment of pluripotent stem cells lines from
magnetically separated cells
In a proof-of-principal study we aimed to establish pluripotent
stem cell lines from magnetically separated cells. We chose a
positive selection strategy based on the well described marker
SSEA1 to demonstrate that iPSC can be established from a
particle-bearing cell fraction. Cells were therefore reprogrammed
Figure 2. Oct4-GFP expression characteristics. A) Immunofluorescence of Oct4-GFP transgenic iPSC line LV1-7b cultured in non-differentiating
conditions. Depicted are the Oct4-GFP marker, staining for OCT4 protein, a DAPI counterstain and phase contrast images. The overlay displays Oct4-
GFP and OCT4 protein. B) The same iPSC line and analysis as in A cultured under differentiating conditions (2 day LIF withdrawal).
doi:10.1371/journal.pone.0102171.g002
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feeder cells 12 days p.t. and separated at day 18 p.t. (Fig. 5A).
After magnetic enrichment for SSEA1, cells were seeded in
limiting dilution assays. Colonies that grew to sufficient size within
6 days and displayed ESC morphology were chosen for expansion
(Fig. 5B). At this stage the clones did also exhibit a homogenous
Oct4-GFP signal. Marker expression was quantified by flow
cytometry demonstrating that all clones consisted of at least 75%
SSEA1
+ and .90% Oct4-GFP
+ cells (data not shown). 6 clones
were subcloned in a second round of limiting dilutions. Flow
Figure 3. Definition of reprogramming stages by Oct4-GFP activation and transgene silencing. A, B) Correlation of OCT4 protein with the
Oct4-GFP reporter expression (A) and the transgenic dTOMATO silencing (B), respectively, was investigated by flow cytometry in hOKSM.idTomato-
transduced cells at different time points of reprogramming (day 4–12). Untransduced, unstained MEFs served as gating control. C) Expression
characteristic of OCT4 protein, Oct4-GFP and SSEA1 as observed in established iPSC clones (passage 9). D) Oct4-GFP expression and transgenic
dTOMATO silencing showed distinct expression characteristics in the course of reprogramming. dTOMATO expression was detectable early during
reprogramming, followed by Tom
+/GFP
+ and Tom
2/GFP
2 intermediate stages, ultimately resulting in a Tom
2/GFP
+ fraction.
doi:10.1371/journal.pone.0102171.g003
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PLOS ONE | www.plosone.org 5 July 2014 | Volume 9 | Issue 7 | e102171Figure 4. Expression kinetics of some candidate markers correlate with reprogramming stages. A) Expression frequencies (mean +/2
SD) of candidate markers on reprogramming subpopulations were investigated by flow cytometry over time (n=3: mean +/2 SD; for SSEA1 n=1)
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Oct4-GFP, OCT4 protein, and remaining expression of transgenic
dTOMATO in a screening experiment to preselect subclones for
further investigation (Fig. 5C). Some subclones demonstrated
residual dTOMATO expression (e.g. the derivatives of R24.23)
and differences between the expression levels of the Oct4-GFP
became obvious. All subclones expressed high levels of SSEA1 and
demonstrated a robust expression of intracellular OCT4 protein. 4
subclones were chosen, each originating from a different parental
clone, and tested in teratoma assays. 3 out of 4 subclones formed
tumors consisting of differentiated tissues originating from the 3
germ layers (Fig. 5D). Importantly, the subclone (R24.23.4) that
failed to produce a tumor exhibited residual transgene expression
at high levels.
In line with previous reports [27], we demonstrated that the
procedure of magnetic cell sorting is well suited for establishment
of pluripotent stem cell lines.
Separation of SSEA1
+, EPCAM
+ or FAS
2 enriches cells
committed to become iPSC
We next sought to examine whether separation by alternative
markers, i.e. the identified reprogramming markers EPCAM and
FAS, is able to improve the procedure in terms of cell yield or
phenotype of the target fraction. Twelve days after induction of
reprogramming in OG2-MEFs magnetic separations were per-
formed comparing the enrichment of SSEA1
+ or EPCAM
+ and
the depletion of FAS
+ cells (Fig. 6A). A representative example for
the efficiency of each separation strategy is given in Figure S3. The
desired target fractions (SSEA1
+, EPCAM
+, FAS
2) typically
achieved purities of 89%, 98% and 98%, respectively (Fig S3).
Each fraction was seeded on top of feeder cells and subsequently
cultured for another 6 days.
Flow cytometric analysis directly after separation demonstrated
that the phenotype of any target fraction was entirely composed of
EPCAM
+/FAS
2 cells independent of the administered separation
strategy (Fig. 6B). Importantly, the SSEA1
+ cells represented a
subfraction of the EPCAM
+ (FAS
2) cells. Consequently, SSEA1
enrichment yielded 6-fold less cells (data not shown), but led to an
accordingly higher population frequency of SSEA1
+ cells.
Remarkably, only FAS depletion completely eliminated the
Tom
high subpopulation in the target fraction, thereby removing
cells with diminished transgene silencing.
Six days after separation all three separation strategies (FAS,
SSEA1 and EPCAM) had led to a similar and significant
enrichment of the Oct4-GFP expressing cells (85%, 84% and
65%, respectively), confirming that any of the given strategies is
suitable to enrich cells poised to become iPSC (Fig. 6C). Notably,
though the respective magnetic isolation protocols were mainly
optimized to yield highly pure target fractions (i.e. the column
flow-through or ‘‘negative’’ fraction for FAS, and eluted or
‘‘positive’’ fraction for SSEA-1 and EPCAM, Fig S3), reduced
ratios of GFP+ cells (yet statistically insignificant) were observed in
the non-target fractions of FAS and EPCAM when compared to
the unseparated cells 6 days after separation (data not shown).
In summary, both EPCAM enrichment and FAS depletion were
characterized by an enhanced cell yield compared to SSEA1
enrichment. FAS depletion represented the only strategy that
enabled the complete removal of the transgene expressing Tom
high
cell population.
Tissue distribution of potential reprogramming markers
on various human cell types
The tissue distribution of some of the candidate markers on
various human cell types was investigated using the Genevestigator
software tool [28], which utilizes publicly available microarray
data sets. To estimate whether the markers might also be suitable
to selectively enrich reprogrammed cells from alternative human
source tissues, we examined mRNA expression of the candidate
genes in different tissues and cell lines. The excerpt given in
Figure 7 focuses on cell types that are easily accessible and had
repeatedly been reprogrammed in previous reports (fibroblasts,
blood cells, skin, adipocytes). mRNA of pluripotency associated
marker EPCAM had not been detected in human fibroblasts,
adipose tissue and various blood cell subtypes (Fig. 7). In line with
these data we found EPCAM protein to be expressed by hiPSC
lines, but not human foreskin fibroblasts (hFF) and human
umbilical vein endothelial cells (hUVEC) (Fig. 8A, B). It might
thus be possible to also employ EPCAM-enrichment for isolation
of iPSC in the human system, if fibroblasts or endothelial cells are
to be reprogrammed. Since EPCAM is a well known epithelial
surface protein, its mRNA was expressed in epithelial cell sources
(Fig. 7), arguing against hiPSC enrichment via EPCAM from this
cell type. In contrast, mRNA of somatic marker FAS seemed to be
expressed not only by fibroblasts and blood cells but also epithelial
cells (Fig. 7), thereby potentially enabling the isolation of hiPSC
from epithelial tissues. While FAS protein was indeed found to be
expressed significantly less in hiPSC than in hFF (Fig. 8A, B), a
subpopulation of these hiPSC expressed low amounts of FAS
protein. Noteworthy, FAS protein was only weakly expressed in
hUVEC. Future investigations are therefore required to assess the
suitability of FAS (and also EPCAM) for isolation of iPSC from
human tissues.
Altogether, we demonstrated the suitability of SSEA1, EPCAM
and FAS for enrichment of iPSC from mouse embryonic
fibroblasts. Moreover, we hypothesize that EPCAM and FAS
selection strategies might also be useful for isolation of iPSC from
various human cell types.
Discussion
Usage of surface markers to identify reprogramming stages can
be readily applied to unmodified cells and allows for live-cell
imaging and antibody-based separation strategies. Accordingly,
some differentially regulated mouse surface markers have already
been utilized for selective isolation of reprogramming subpopula-
tions. These markers include SSEA1, which was previously shown
to be upregulated as one of the earliest markers in reprogramming
[11;12]. EPCAM, which has been shown to actively promote
cellular reprogramming [29], also allowed for successful enrich-
ment of NANOG-expressing cells [18]. Combinations of PE-
CAM1 with SSEA1, ITGA6, PVRL2 and EPCAM, respectively,
were shown to enrich the fraction of pluripotency factor expressing
cells [19]. Also, the combination of PGP-1/ICAM1/Nanog-GFP
was recently suggested to provide high-resolution information
during late pluripotency gene upregulation [20], although without
providing a generic marker code enabling the isolation of iPSC
generated from wild type cells. Likewise though with different
intention surface marker SSEA1 was used to deprive iPS-derived
neuronal cells of remaining pluripotent cells [22] Nonetheless, only
(also see Figure S2). Reprogramming subpopulations were defined as shown in Fig. 3D. B) Correlation of ITGAV, SSEA1, EPCAM and FAS with
expression of OCT4 protein as analyzed by flow cytometry at day 12 p.t. C) Likewise, correlation of the selected candidate markers with the Oct4-GFP
reporter system is shown at day 12 of reprogramming.
doi:10.1371/journal.pone.0102171.g004
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potential to discriminate distinct stages of reprogramming.
We therefore aimed to employ a panel of 170 antibodies to
detect expression of surface proteins on MEFs and PSC and were
able to identify 12 differentially expressed proteins. We investi-
gated expression changes of these respective markers in distinct
reprogramming subpopulations. Combining a traceable lentiviral
expression system with a transgenic Oct4-GFP reporter system, we
Figure 5. Establishment of iPSC lines from magnetically separated cells. A) Schematic overview of the procedure. After induction of
reprogramming cells were once harvested and transferred on irradiated feeders. Isolation of SSEA1
+ cells was performed 18 days p.t., diluted to a cell
density of 5 cells/ml and 0.1 ml transferred per well of 96well plates (statistically 0.5 cells/well). B) 6–8 days after limiting dilution colonies of sufficient
size and typical ESC-like morphology were chosen for expansion. Most colonies already demonstrated a strong and homogenous GFP signal. A
representative colony is depicted. Expanded clones were subcloned in a second limiting dilution and expanded as described above. C) To pre-select
subclones with the most promising potential for pluripotency several subclones of each clone were screened for expression levels of Oct4-GFP and
SSEA1 (left plot) as well as expression of intracellular OCT4 and silencing of transgenic dTOMATO (right plot, n=1). D) When injected into
immunodeficient mice, 3 out of 4 subclones gave rise to teratomas with differentiation into derivatives of the 3 germ layers. Depicted is
representative subclone R24.16.5 that formed keratinizing epithelium (ectoderm), cartilage (mesoderm) and pancreas-like glandular structures
(endoderm).
doi:10.1371/journal.pone.0102171.g005
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PLOS ONE | www.plosone.org 8 July 2014 | Volume 9 | Issue 7 | e102171Figure 6. Separation of SSEA1
+, EPCAM
+ or FAS
2 cells allows for enrichment of Oct4-GFP reporter-positive cells. A) Timeline of
reprogramming, cell separation and analyses. OG2 were seeded one day prior to viral transduction. Cells were magnetically separated at day 12 p.t.
(see Figure S3 for efficiencies) and fractions further cultured on irradiated feeder cells for another 6 days. Flow cytometric analyses of all separated
fractions were performed directly after separation and after further culture. B) Depicted are the expression characteristics of the target fractions of
each separation strategy (SSEA1
+, EPCAM
+ and FAS
2) as measured directly after separation by flow cytometry. Pairwise correlations of SSEA1/EPCAM
(upper panel), FAS/EPCAM (middle panel) and hOKSM.idTomato/Oct4-GFP (lower panel) are shown. Unseparated cells are shown in the left column.
C) The percentages of Oct4-GFP expressing cells in the different fractions are shown for magnetic separations based on SSEA1, EPCAM or FAS.
Analyses were performed 6 days after separation by flow cytometry. p values were calculated with a Student’s t test. *p,0.05; **p,0.01; ***p,0.001.
Scale bars show the SD for three separate experiments (alpha=95%).
doi:10.1371/journal.pone.0102171.g006
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stages were characterized by silencing of vector transgenes, which
was previously described as hallmark of reprogramming [12;15–
17;26], and reactivation of the Oct4-GFP reporter. Previous
reports demonstrated the suitability of combined approaches of
transgene silencing and pluripotency factor (NANOG, SOX2)
reactivation that were shown to reflect progression through the
different stages of reprogramming [14;30]. We found that reporter
signals from our transgenic Oct4-GFP cassette succeeded the
endogenous reactivation of OCT4 protein during reprogramming
but established a full correlation in established iPSC, representing
a conservative indicator of OCT4 expression. Despite the delayed
expression characteristics of the Oct4-GFP signal, it correlated
entirely with the expression intensity of the reprogramming
factors, i.e. first with the Tom
low and later with the Tom
2
subpopulation. We concluded that our combined system is thus
suitable to define sequential reprogramming stages.
Employing this two-reporter-system we were able to investigate
the kinetic changes of our potential reprogramming markers in the
course of reprogramming. We confirmed the sequential upregula-
Figure 7. Excerpt of the tissue distribution of EPCAM and FAS mRNA in human cell types. An mRNA analysis based on the Genevestigator
software tool was performed reflecting the tissue distribution of investigated mRNAs. Shown are selected tissues that are relatively easily accessible
and have already been reprogrammed in previous reports. The ‘‘percentage of expression potential’’ represents the average expression of a gene
across all samples of the particular cell type as compared to the sample with the highest expression (maximum level, 100%) for the particular gene
[percentage of expression potential = average/maximum]. The number of samples that were included to calculate this average is indicated on the
right side of the graph. Results are given as logarithmic (log2) heat map.
doi:10.1371/journal.pone.0102171.g007
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studies had revealed a function of EPCAM in maintenance of the
undifferentiated phenotype in mouse and human ESC [32;33].
Importantly, this function is exerted by regulation of pluripotency-
associated factors, such as OCT4, SOX2, KLF4, C-MYC and
NANOG [33]. In line with these findings, we could observe that
EPCAM expression correlated with expression of OCT4 protein
even in cells that had already silenced the transgenic reprogram-
ming factors as indicated by loss of Tom expression. Noteworthy, a
recent study suggested EPCAM to be as informative to predict the
iPSC state as NANOG and LIN28 [31]. Since upregulation of
EPCAM precedes the expression of SSEA1, the latter marker was
shown to detect only a subpopulation of the OCT4 expressing
(EPCAM
+) cells. Interestingly, besides SSEA1 also the Oct4-GFP
reporter succeeded OCT4 protein expression. However, both
markers did not correlate with one another in early reprogram-
ming, suggesting independent induction of the two markers. Co-
expression with robust expression levels was finally observed after
establishment of iPSC lines. While our antibody screen had
revealed expression of C-KIT by PSC, we observed only marginal
expression in the Oct4-GFP single positive stage until day 12 of
reprogramming. Recent data suggest that this protein might
represent an intermediate marker of reprogramming progression
[31] and would thus also be an interesting candidate for separation
of iPSC. Likewise, DDR2, which demonstrated similar expression
kinetics as C-KIT in our study, might be an additional candidate
for further experiments. Interestingly, our data does not corrob-
orate the recently reported ICAM1+/PGP-1- signature of late
reprogramming stages [20]. We found ICAM1 to be broadly
expressed on the MEF population as well as on iPS (Table S1).
PGP-1 was excluded from isolation studies due to the lacking
correlation with mature reprogramming stages defined by our dual
reporter system.
To our knowledge, we are the first to characterize expression
dynamics of FAS in the course of reprogramming of MEF into
iPSC. FAS was quickly downregulated on OG2-MEFs upon
Figure 8. Expression analysis of EPCAM and FAS protein in selected human cell types. A, B) Flow cytometry analysis of FAS and EPCAM
expression on human foreskin fibroblasts (hFF), human umbilical vein endothelial cells (hUVEC) and two hiPSC lines. A) Representative flow cytometry
analysis results. B,) Independent quantification of relative expression levels of FAS and EPCAM for the same four cell types. Stain indices (SI) are
depicted to enable the comparison of expression levels for cell types displaying different levels of autofluorescence. SI were calculated as follows:
(Median of labeled cells – Median of unlabeled cells)/(26standard deviation of unlabeled cells). p values were calculated with a Student’s t test. *p,
0.05; **p,0.01; ***p,0.001. Scale bars show the SD for three separate experiments (alpha=95%).
doi:10.1371/journal.pone.0102171.g008
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previous reports suggesting the absence of FAS expression in naı ¨ve
mouse ES cells [34;35]. Furthermore, the expression of FAS was
reported to be regulated by cooperating transcription factors, e.g.
repression of FAS expression by OCT4 [36;37]. This is in line with
our data demonstrating anti-correlation of FAS and OCT4
protein expression. In addition, activated tumor suppressor protein
P53 positively correlates with FAS expression levels [37–40] and
vice versa. Importantly, inhibition of P53 has been shown to
enhance reprogramming efficiencies [41]. It would thus be
interesting to investigate, whether FAS downregulation actively
promotes reprogramming or is a consequence of negative
regulation by OCT4 and lacking upregulation by P53.
In our study we were able to confirm, that not only pluripotency
marker upregulation but also downregulation of a somatic marker
can be applied when isolating iPSC [20]. We suggest that
downregulation of FAS, which is strongly expressed on MEFs,
enables the enrichment of cells poised to become iPSC. A direct
comparison of EPCAM- or SSEA1-enrichment with FAS-deple-
tion demonstrated similar frequencies of Oct4-GFP
+ cells in the
SSEA1
+ and FAS
2 target fractions after a subsequent culture
period. Though all sorting paradigms led to a robust enrichment
of Oct4-GFP
+ cells, minor fractions of Oct4-GFP
2 were detectable
6d after isolation. These Oct4-GFP
2 could represent either a)
spontaneously differentiated iPSC, b) reprogramming cells with
retarded kinetics or c) cells which have not fully matured after
having initiated the reprogramming process [42]. Isolation of the
EPCAM
+ fraction resulted in a slightly lower frequency of Oct4-
GFP
+ cells. This is in line with our observation that SSEA1
+ cells
arose as a subfraction of the EPCAM
+ population, reflecting that
EPCAM is upregulated even before SSEA1. Although the SSEA1
+
cells also represent a subpopulation of FAS
2 cells, FAS depletion
worked equally well as SSEA1-enrichment. In consequence,
selection strategies based on EPCAM as well as FAS yield higher
cell numbers with comparable potential to SSEA1
+ cells.
Considering that only depletion of FAS expressing cells was able
to completely abolish the fraction of immature, transgene
dependent Tom
high cells from the reprogramming culture, it is
tempting to hypothesize that lack of FAS indicates a more mature
reprogramming stage with a higher degree of epigenetic remod-
eling. It would thus be interesting to address the functional
relevance of FAS for cellular reprogramming in future studies.
By enrichment of SSEA1
+ cells we have exemplified that the
procedure of magnetic separation is well suited for the establish-
ment of pluripotent stem cell lines even from a particle-bearing cell
fraction. Established iPSC lines demonstrated pluripotency to the
level of teratoma formation with differentiation into tissues derived
from the 3 germ layers. Likewise, Dick and colleagues observed no
adverse effects of magnetic particles when transducing cells with
magnetic-particle-bearing lentiviruses and were able to establish
hiPSC lines from positively selected human cells [27]. Importantly,
magnetically separated cells are frequently reported to result in
stable engraftment and survival of transplanted cells in vivo, e.g.
using ES-derived cells [43;44] or in cancer treatment [45–49].
Thus, magnetic separation is suitable for rapid enrichment of
pluripotent cells and a robust method for clinical therapies.
To date, we demonstrated the selective enrichment of iPSC
derived from mouse embryonic fibroblasts. However, for future
clinical applications selection strategies for human iPSC are
needed. In addition, it might be of interest to reprogram cell types
that are more easily accessible and can be obtained in sufficient
amounts. We thus inspected the mRNA expression patterns as
observed in various human tissues based on numerous publicly
available microarray data sets. These data suggest that FAS might
serve to isolate hiPSC from epithelial cells, while EPCAM as
known epithelial marker cannot be employed. This example
highlights the need to take the cellular background into account
when selecting a suitable marker for separation. Protein data
moreover demonstrated significant expression differences of FAS
between fibroblasts and hiPSC derived thereof. Furthermore,
EPCAM expression differed significantly between hFF and hFF-
derived iPSC and hUVEC and hCBEC-derived iPSC, respective-
ly. Although the collective data support the notion that FAS and
EPCAM might also be suitable to isolate iPSC in the human
system, expression kinetics need to be investigated and separations
to be tested to draw definite conclusions. Noteworthy, in contrast
to its expression on mouse pluripotent stem cells SSEA1 is only
expressed on a differentiating subpopulation of human PSC
cultures [50;51]. Therefore, it cannot be used to positively select
for potential iPSC from human reprogramming cultures. Instead,
alternative markers have been employed in proof-of-principle
studies including SSEA4, TRA-1-60, TRA-1-81 and TNSFS8
(CD30) [27;52–56]. Additionally, combinations of the positive
markers SSEA4 and TRA-1-60 with the negative marker
Aminopeptidase N (CD13) have been used for selection of human
pluripotent stem cells [56].
In conclusion, we reported 12 naturally occurring surface
proteins that are differentially expressed between mouse embry-
onic fibroblasts and pluripotent stem cells. SSEA1, EPCAM and
FAS allow the selective enrichment of cells poised to become iPSC
from reprogramming MEF cultures by magnetic separation,
thereby overcoming low efficiencies and easing the generation of
iPSC lines. We hypothesize that some of these separation strategies
can also be used to enrich iPSC from human source tissues and
that they can aid the generation of patient- and disease-specific
iPSC for research and clinical applications.
Materials and Methods
Ethical Statement
This study was conducted in accordance with the German
animal protection law and with the European Communities
Council Directive 86/609/EEC for the protection of animals used
for experimental purposes. All experiments were approved by the
Hannover Medical School Institutional Animal Care and
Research Advisory Committee and permitted by the local
government (LAVES, permit number 10/0209) according with
the German animal protection law and with the European
Communities Council Directive 86/609/EEC for the protection
of animals used for experimental purposes.
Cell culture
293T human epithelial kidney cells (CCL-121) and HT1080
human fibrosarcoma cells (CRL-3216) were purchased from
ATCC and maintained in Dulbecco’s modified Eagle’s medium
(Miltenyi Biotec, Bergisch Gladbach, Germany), 10% fetal calf
serum (FCS) (PAA, Co ¨lbe, Germany). MEFs were prepared from
day 13.5 embryos of CF1 (Charles River) or Oct4-GFP (OG2) mice
strains [25] and cultured on 0.1% gelatin-coated dishes in MEF
medium (Dulbecco’s modified Eagle’s medium, 10% FCS, 1%
non-essential amino acids (NEAA), 2 mM L-glutamine (all from
PAA) and 100 mM b-mercaptoethanol (b-ME) (Sigma-Aldrich,
Munich, Germany)). Feeder-dependent mouse ES cells (HM1)
[57], obtained from Dr. Douglas Melton (Harvard University
Cambridge, MA, USA), the iPS-line LV1-7b [24] and newly
generated iPS cells were cultured on gamma-irradiated CF1-
MEFs in iPSC medium (Knockout-DMEM (Invitrogen, Darm-
stadt, Germany), 15% ES-grade FCS (PAN, Aidenbach, Ger-
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ml mouse LIF (Miltenyi Biotec). Mouse PSC lines were splitted
every two days seeding 1–2610
5 cells per 6 well dish. Optionally,
mouse PSC were additionally cultured under ‘‘3i’’ conditions [58–
60] (1 mM PD0325901, 3 mM CHIR99021 and 4 mM SB431542;
all from Stemgent, Cambridge, MA, USA). Feeder-independent
mouse ES cells (CM7/1) [61], obtained from Dr. Robert
Zweigerdt (REBIRTH, Hannover Medical School, Germany)
were cultured on 0.1% gelatin-coated plates in ES-medium
(DMEM, 10% ES-grade FCS, 1% NEAA and 100 mM b-ME
and 22 U/ml mouse LIF). Human BJ-fibroblast (08-0027) were
purchased from Stemgent and maintained in Dulbecco’s modified
Eagle’s medium supplied with 10% FCS, 1% non-essential amino
acids (NEAA), 2 mM L-glutamine (all from PAA). Human BJ-
fibroblast-derived iPSC (hFF-iPS) were generated using the
mRNA Reprogramming Kit (Stemgent) according to the manu-
facturer’s instructions. Human cord blood endothelial cell-derived
iPSC (hCBEC-iPS) [62], obtained from Dr. Ulrich Martin
(REBIRTH, Hannover Medical School, Germany) and hFF-iPS
were maintained on gamma-irradiated CF1-MEFs in hiPSC
medium (D-MEM/F12, 20% KO-Serum Replacement (Invitro-
gen), 1% NEAA, 1 mM L-glutamine, 100 mM b-ME, 8 ng/ml
human FGF-2 premium grade (Miltenyi Biotec)). Cells were
passaged using TrypLE Select (Invitrogen). Medium was supple-
mented with Cloning & Recovery Supplement (Stemgent) for the
first 2 days after replating.
Virus production
Lentiviral particle production was performed as described
previously [63]. A 4-in-1 reprogramming vector harboring 2A-
linked hOct4,h Klf4,h Sox2 and hc-Myc and an IRES-linked dTomato
(hOKSM.idTomato) was used [26]. To determine biological titers,
human HT1080 fibroblasts were transduced with viral superna-
tants and expression of virally delivered fluorescent protein
dTOMATO was measured by flow cytometry 4 days post
transduction (p.t.). Titers were calculated as follows: [(cell number
at transduction) x (frequency of transduced cells) x 2]/(volume of
viral supernatant). Viral transductions were performed in presence
of 10 mM HEPES and 4 mg/ml protamine sulphate (Sigma) for 8–
16 h.
Flow cytometry
For the screening assay cells were harvested using 0.25%
trypsin-EDTA. Reprogramming cultures were harvested as
detailed in the ‘‘Reprogramming’’ paragraph of the Material
and Methods section. For surface marker stains, primary antibody
staining was performed in PEB buffer (PBS/2 mM EDTA/0.5%
BSA) for 10 min at 4uC, if not stated otherwise. Antibodies and
staining conditions of the antibody screening are listed in Table
S1. Moreover, anti-mSSEA1, anti-mITGAV, anti-hCD95 and
anti-hEPCAM were used according to manufacturer’s instructions
(all Miltenyi Biotec). Cells were washed once and, if required,
secondary staining also performed for 10 min at 4uC. Virally
transduced cells were additionally fixed in 1.85% formaldehyde
(Miltenyi Biotec) for 20 min at room temperature before flow
cytometric analysis.
Staining for intracellular OCT4 was conducted after surface
marker staining. According to manufacturer’s instructions (BD,
Heidelberg, Germany) cells were fixed in a 1:1 mixture of Cytofix
and Cytoperm for 20 min at 4uC and subsequently washed in
Perm/Wash solution. The OCT4 intracellular stain was conduct-
ed using anti-Oct4 Alexa Fluor 647 (BD, Heidelberg, Germany)
for 30 min at 4uC and cells were again washed in Perm/Wash. For
flow cytometric analysis cells were resuspended in PEB buffer.
Data were acquired using the MACSQuant Analyzer or
MACSQuant VYB and analyzed with the MACSQuantify
Software.
Stain indices (SI) were calculated as follows: (Median of labeled
cells – Median of unlabeled cells)/(26 standard deviation of
unlabeled cells).
Immunofluorescence
Cells grown in standard culture dishes were rinsed with PBS,
fixed with 4% paraformaldehyde (Merck), permeabilized with
0.1% Triton X-100 (Sigma-Aldrich) and blocked with 10% FCS in
PBS. Cells were incubated with Anti Oct-4 antibody (Santa Cruz
(Heidelberg, Germany) sc-5279, 1:50) in blocking solution for 1 h
at 4uC. Secondary antibody staining was performed for 45 min
(goat anti-mouse-Alexa Fluor 594, Invitrogen), followed by DAPI
staining (Sigma) for 5 min. Cells were covered by mounting
medium (Invitrogen) and analyzed using a Nikon Eclipse TS 100.
Reprogramming
For reprogramming 6,5610
3 MEFs per cm
2 were seeded on
gelatin-coated dishes one day prior to transduction. MEFs were
transduced virally using a multiplicity of infection of 4–7. Medium
was changed to MEF medium 8–16 h p.t. Cells were further
cultured in MEF medium until day 4 p.t. and in iPSC medium
hereafter. Medium was exchanged every other day supplemented
with 2 mM valproic acid (Merck, Darmstadt, Germany) from day
2 onwards, 25 mg/ml vitamin C (Sigma-Aldrich) from day 2–8 and
‘‘3i’’ cocktail from day 8 onwards. To harvest the cells, dishes were
washed once in PBS, pre-treated with 1 mg/ml Dispase (Roche,
Penzberg, Germany) for 7 min at 37uC, washed and dissociated in
0.25% trypsin-EDTA (Sigma-Aldrich) for 5 min at 37uC.
Magnetic cell separation
Reprogrammed cells were harvested as described above. Cell
suspensions were filtered via 30 mM pre-separation filters (Miltenyi
Biotec). Magnetic separations were performed according to
manufacturer’s protocol. In brief, 5610
6 cells were magnetically
labeled as follows. For FAS separation (indirect separation) cells
were first stained with 1 mg/ml primary antibody (Anti-FAS-
Biotin) for 10 min at 4uC in 0.1 ml of PEB buffer, washed by
addition of 2 ml buffer, centrifuged and resuspended in buffer.
Magnetic labeling in general was performed for 15 min at 4uCi n
0.1 ml of a 1:5 dilution of the according MicroBeads in PEB (Anti-
SSEA-1 (CD15)-MicroBeads (Miltenyi Biotec 130-094-530), Anti-
Biotin-MicroBeads (Miltenyi Biotec 130-090-485) and Anti-
EpCAM-MicroBeads, respectively). Cell suspensions were then
washed in PEB and resuspended in 0.5 ml iPS-Medium without
LIF. Columns were pre-equilibrated and placed in appropriate
magnets. Cells suspensions were administered and columns
afterwards washed with medium by gravity flow. The entire
flow-through was collected as negative fraction. Positive fractions
were eluted in required volumes using the provided plunger.
EPCAM and SSEA1 separations were carried out using MS
columns, FAS separations using LD columns. After separation,
cells were investigated by flow cytometry or seeded on top of
CellTrace Violet Dye pre-stained (Invitrogen) gamma-irradiated
feeder cells (1610
5 cells per well of a 12well plate). Seeded cells
were further cultured in ‘‘3i’’ conditions for 6 days with media
changes every other day.
Establishment of iPSC lines after magnetic separation
Limiting dilutions were performed to isolate single cells after
separation. Separation based on SSEA1 was performed at day
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conditions to a cell density of 5 cells/ml. 0.1 ml of this cell
suspension was seeded per well of a 96well plate containing
gamma-irradiated CF1-MEFs and further cultured for 6–8 days.
Single colonies were expanded and analyzed by flow cytometry.
Lines that expressed highest levels of SSEA1 were subcloned by a
second round of limiting dilutions to ensure clonality of derived
iPSC lines.
Teratoma assay
iPSC were harvested, 1610
6 cells resuspended in 0.2 ml PBS
and injected subcutaneously into the flanks of six NOD.Cg-
Rag1tm1Mom Il2tm1Wjl/Sz (NRG) mice. Teratoma formation
occurred 4–8 weeks after injection. During this time frequent
checking of the teratoma formation ensured the termination of the
experiment at the approved state. The guidelines issued from the
GV-Solas (Society for Laboratory Animal Science) and TVT
(Veterinary association for Animal Welfare, Germany) served as
basis for defining the humane endpoints. After anesthesia using
carbon dioxide, animals were sacrificed by cervical dislocation.
Teratomas were fixed in 4% neutral buffered formalin (pH 7.2),
embedded in paraffin and 2 mm sections Hematoxylin & Eosin
stained.
Microarray meta-analysis
Publicly available microarray datasets were analyzed using the
Genevestigator anatomy tool [28]. This tool displays expression
levels of genes of interest in various tissues and cell lines. The
expression level within a tissue type is the average expression
across all samples that were annotated with that particular cell
type. Data sets analyzed in this study were derived on Affymetrix
microarray ‘‘Human133_2: Human Genome 47k array’’.
Statistical Analysis
Throughout the paper, p values were calculated with Student’s t
tests. *p,0.05, **p,0.01, ***p,0.001. Scale bars show the SD of
at least three separate experiments unless otherwise stated
(alpha=95%).
Supporting Information
Figure S1 Expression intensity of candidate markers on
the Oct4-GFP transgenic MEFs. A) Mean fluorescence
intensity of potential MEF associated markers as determined by
flow cytometry. B) Expression levels of potential pluripotency
associated markers.
(TIF)
Figure S2 Expression characteristics of candidate
markers on the different reprogramming subpopula-
tions. The expression frequencies of potential pluripotency
associated markers (left column) and potential MEF associated
markers (right column) as observed in cell subpopulations
progressing through reprogramming. Frequencies were examined
by flow cytometry (n=3: mean +/2 SD).
(TIF)
Figure S3 Efficiencies of magnetic separations from
reprogramming MEFs. The frequencies of the respective
markers used for separation are shown for unseparated fractions
and target fractions (SSEA1
+, EpCAM
+ and FAS
2).
(TIF)
Table S1 Marker expression frequencies as detected in
the antibody screening experiment. Altogether 170 anti-
bodies were screened. Given are details on antibody vendors and
staining conditions. The frequencies of positive cells among CF1-
MEFs, HM1-ESCs and LV1-7b-iPSCs (in percent) are listed for
each individual replicate. n.a. = not available.
(XLS)
Checklist S1 (PDF)
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